These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28860437)

  • 1. [IV. Development and Future Perspective of Immune Checkpoint Blockade Therapy].
    Tamada K
    Gan To Kagaku Ryoho; 2017 Aug; 44(8):661-665. PubMed ID: 28860437
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.
    Li X; Song W; Shao C; Shi Y; Han W
    Cell Mol Immunol; 2019 Jan; 16(1):28-39. PubMed ID: 30002451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large-scale public data reuse to model immunotherapy response and resistance.
    Fu J; Li K; Zhang W; Wan C; Zhang J; Jiang P; Liu XS
    Genome Med; 2020 Feb; 12(1):21. PubMed ID: 32102694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of novel immunotherapy targeting cancer immune evasion].
    Tamada K
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1062-5. PubMed ID: 25248888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study May Change Approach to Immunotherapy.
    Cancer Discov; 2016 May; 6(5):OF1. PubMed ID: 27012834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genome-Based Biomarkers of Immune Checkpoint Blockade Therapy].
    Adachi K; Tamada K
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):143-50. PubMed ID: 27067677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A special issue dedicated to immuno-oncology].
    Bibeau F; Badoual C
    Ann Pathol; 2017 Feb; 37(1):1-2. PubMed ID: 28109693
    [No Abstract]   [Full Text] [Related]  

  • 8. Preclinical imaging for targeting cancer immune evasion.
    Terlizzi C; De Rosa V; Iommelli F; Altobelli GG; Fonti R; Del Vecchio S
    Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):186-193. PubMed ID: 32286769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled in vivo screens for cancer immunotherapy target discovery.
    Lane-Reticker SK; Manguso RT; Haining WN
    Immunotherapy; 2018 Mar; 10(3):167-170. PubMed ID: 29370725
    [No Abstract]   [Full Text] [Related]  

  • 10. [Basics of cancer immunotherapy].
    Fujioka Y; Nishikawa H
    Rinsho Ketsueki; 2016; 57(11):2346-2354. PubMed ID: 27941285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker search illuminates cancer immune biology.
    Kingwell K
    Nat Rev Drug Discov; 2016 Jun; 15(7):443-5. PubMed ID: 27357009
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer Neoantigens and Applications for Immunotherapy.
    Desrichard A; Snyder A; Chan TA
    Clin Cancer Res; 2016 Feb; 22(4):807-12. PubMed ID: 26515495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y; Choudhury A; Kiessling R
    Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies.
    Jacob JA
    JAMA; 2015 Nov; 314(20):2117-9. PubMed ID: 26599172
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of PD-1 blockade in tumors with MMR deficiency.
    Lee V; Le DT
    Immunotherapy; 2016; 8(1):1-3. PubMed ID: 26643016
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined Immune Checkpoint Blockade.
    Drake CG
    Semin Oncol; 2015 Aug; 42(4):656-62. PubMed ID: 26320068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cancer immunotherapy by immuno-checkpoint blockade].
    Kawakami Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of biomarker expression to characterize neoplastic processes.
    Grizzle WE; Myers RB; Manne U
    Biotech Histochem; 1997 Mar; 72(2):96-104. PubMed ID: 9152522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy].
    Hatae R; Chamoto K
    Rinsho Ketsueki; 2016; 57(10):2224-2231. PubMed ID: 27795534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.